Neurocrine Biosciences, Inc. (NBIX)

Neurocrine Biosciences Stock Forecast

Stock Price Forecast

The 18 analysts that cover Neurocrine Biosciences stock have a consensus rating of "Strong Buy" and an average price target of $160.94, which forecasts a 15.29% increase in the stock price over the next year. The lowest target is $115 and the highest is $185.

Price Target: $160.94 (+15.29%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$115	$160.94	$165	$185
Change	-17.62%	+15.29%	+18.19%	+32.52%

* Price targets were last updated on Aug 1, 2025.

Analyst Ratings

The average analyst rating for Neurocrine Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Mar '25	Apr '25	May '25	Jun '25	Jul '25	Aug '25
Strong Buy	6	7	7	7	10	9
Buy	11	11	11	11	9	7
Hold	4	2	2	2	3	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	21	20	20	20	22	18

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Yatin Suneja Guggenheim	Guggenheim	Strong Buy Maintains $165 → $175	Strong Buy	Maintains	$165 → $175	+25.36%	Aug 1, 2025
Anupam Rama JP Morgan	JP Morgan	Hold Maintains $140 → $145	Hold	Maintains	$140 → $145	+3.87%	Jul 31, 2025
Brian Abrahams RBC Capital	RBC Capital	Buy Maintains $146 → $144	Buy	Maintains	$146 → $144	+3.15%	Jul 31, 2025
Paul Matteis Stifel	Stifel	Strong Buy Maintains $166 → $174	Strong Buy	Maintains	$166 → $174	+24.64%	Jul 31, 2025
Jeffrey Hung Morgan Stanley	Morgan Stanley	Buy Maintains $150 → $158	Buy	Maintains	$150 → $158	+13.18%	Jul 31, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

2.84B

Increased by 20.66%

from 2.36B

Revenue Next Year

3.26B

Increased by 14.64%

from 2.84B

EPS This Year

4.52

Increased by 37.34%

from 3.29

EPS Next Year

6.58

Increased by 45.56%

from 4.52

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	1.05B	1.13B	1.49B	1.89B	2.36B	2.84B	3.26B
Revenue Growth	32.71%	8.38%	31.34%	26.76%	24.81%	20.66%	14.64%
EPS	4.16	0.92	1.56	2.47	3.29	4.52	6.58
EPS Growth	966.67%	-77.89%	69.57%	58.33%	33.20%	37.34%	45.56%
Forward PE	-	-	-	-	-	30.89	21.22
No. Analysts	-	-	-	-	-	30	29

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	3.0B	3.6B
Avg	2.8B	3.3B
Low	2.7B	2.8B

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	28.1%	25.9%
Avg	20.7%	14.6%
Low	12.9%	-2.9%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	5.58	8.94
Avg	4.52	6.58
Low	3.51	4.08

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	69.5%	97.7%
Avg	37.3%	45.6%
Low	6.6%	-9.8%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.